Home/Filings/4/0001140361-24-041408
4//SEC Filing

Buchanan Lucas W. 4

Accession 0001140361-24-041408

CIK 0001397702other

Filed

Sep 17, 8:00 PM ET

Accepted

Sep 18, 8:23 PM ET

Size

13.2 KB

Accession

0001140361-24-041408

Insider Transaction Report

Form 4
Period: 2024-09-17
Buchanan Lucas W.
Chief Financial Officer
Transactions
  • Disposition to Issuer

    Common Stock

    2024-09-1713,5180 total(indirect: See footnote)
  • Disposition to Issuer

    Common Stock

    2024-09-17503,2950 total
  • Award

    Common Stock

    2024-09-17+50,87650,876 total
  • Disposition to Issuer

    Common Stock

    2024-09-1750,8760 total
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2024-09-17$7.50/sh5,331$39,9830 total
    Exercise: $20.00Exp: 2029-04-03Common Stock (5,331 underlying)
Footnotes (8)
  • [F1]Of the reported shares, 358,590 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
  • [F2]Includes 2,000 shares and 370 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on May 20, 2024 and September 13, 2024, respectively.
  • [F3]Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.
  • [F4]Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
  • [F5]Immediately prior to the effective time of the merger, certain RSUs subject to the achievement of performance-based criteria, or PSUs, were deemed achieved and certified by the Issuer's compensation committee.
  • [F6]Pursuant to the Merger Agreement, each PSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the PSUs, less applicable taxes and authorized deductions.
  • [F7]These shares are held directly by the Buchanan Grandchildren's Irrevocable Trust, for which the reporting person serves as a co-trustee.
  • [F8]The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $39,982.50, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Issuer

Silk Road Medical Inc

CIK 0001397702

Entity typeother

Related Parties

1
  • filerCIK 0001769830

Filing Metadata

Form type
4
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 8:23 PM ET
Size
13.2 KB